LEI:
549300Q7EXQQH6KF7Z84
01 May 2024
RTW Biotech Opportunities
Ltd
(the "Company")
Total Voting
Rights
In accordance with
the FCA's Disclosure Guidance and Transparency Rule
5.6.1R the Company would like to notify the market of the
following:
At the close of business on 30 April
2024, the Company had 394,290,303 Ordinary shares in issue, of
which 9,603,791 were held in Treasury. Therefore, the total
number of voting rights in the Company was
384,686,512**.
The above figure of 384,686,512 may
be used by Shareholders as the denominator for the calculations by
which they will determine if they are required to notify their
interest in, or a change to their interest in, the Company under
the FCA's Disclosure Guidance and Transparency
Rules.
**As per the "Completion of
Acquisition" announcement published on 13 February 2024, the
denominator used for the NAV per share calculation will exclude the
48,322,863 New RTW Bio Shares issued to RTW Biotech Opportunities
Operating Ltd in respect of its shareholding in Arix held by the
Company.
For
Further Information:
|
RTW
Investments, LP
|
+44
(0)20 7959 6361
|
|
Woody Stileman, Managing
Director
Krisha McCune, Director, Investor
Relations
|
|
|
|
|
About RTW Biotech Opportunities Ltd:
RTW Biotech Opportunities Ltd (LSE:
RTW & RTWG) is an investment fund focused on identifying
transformative assets with high growth potential across the
biopharmaceutical and medical technology sectors. Driven by a
long-term approach to support innovative businesses, RTW Biotech
Opportunities Ltd invests in companies developing next-generation
therapies and technologies that can significantly improve patients'
lives. RTW Biotech Opportunities Ltd is managed by RTW Investments,
LP, a leading healthcare-focused
entrepreneurial investment firm with
deep scientific expertise and a strong track record of supporting
companies developing life-changing therapies.
Visit the website
at www.rtwfunds.com/rtw-biotech-opportunities-ltd for
more information.